

MAR 29 2002

**Special 510(k) Summary: Design Modification of the Dyax Lag Screw
to the Gamma 3 Lag Screw**

Submission Information

Name and Address of the Sponsor of the 510(k) Submission: Howmedica Osteonics Corp
59 Route 17
Allendale, NJ 07401-1677

Contact Person: Karen Ariemma
Regulatory Affairs Specialist

Date of Summary Preparation: February 27, 2002

Device Identification

Proprietary Name: Gamma 3 Lag Screw
Common Name: Intramedullary Nail
Classification Name and Reference: Intramedullary Fixation Rod, 21 CFR §888.3020

This Special 510(k) submission is intended to address a design modification of the Dyax Lag Screw to create the subject device which is referred to as the Gamma 3 Lag Screw. The design modification involves changes to the thread diameter; thread radius and cutting flute design. The subject device is intended to be used with both the Long Length Dyax Nail and the Trochanteric Dyax Nail. The design modification involves changes to the thread diameter; thread radius and cutting flute design

There is no change in intended use for the modified device when compared to the previously cleared product. The subject Gamma 3 Lag Screws are substantially equivalent to the existing design of Dyax Nail Lag Screw that were determined substantially equivalent via the 510(k) process.

KO200677
page 1 of 1



MAR 29 2002

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Karen Ariemma
Regulatory Affairs Specialist
Howmedica Osteonics Corporation
59 Route 17
Allendale, New Jersey 07401-1677

Re: K020677
Trade/Device Name: Gamma 3 Lag Screw
Regulation Number: 888.3020
Regulation Name: Intramedullary fixation rod
Regulatory Class: II
Product Code: HSB
Dated: February 27, 2002
Received: March 1, 2002

Dear Ms. Ariemma:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 – Ms. Karen Ariemma

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

for Mark N. Witten

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

